Trexquant Investment LP Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Trexquant Investment LP purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,129 shares of the company’s stock, valued at approximately $1,195,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. purchased a new position in Axsome Therapeutics during the fourth quarter worth about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $64,000. KBC Group NV raised its position in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the period. Xponance Inc. lifted its holdings in Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock valued at $225,000 after acquiring an additional 277 shares during the last quarter. Finally, Intrust Bank NA grew its position in Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock worth $239,000 after acquiring an additional 183 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Down 5.9 %

Shares of Axsome Therapeutics stock opened at $95.65 on Friday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The business’s fifty day moving average price is $119.81 and its two-hundred day moving average price is $101.93. The company has a market capitalization of $4.66 billion, a P/E ratio of -15.97 and a beta of 0.88.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. As a group, research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group began coverage on Axsome Therapeutics in a research note on Monday. They issued a “buy” rating and a $200.00 price objective for the company. Mizuho lifted their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Finally, Royal Bank of Canada lifted their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $169.80.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.